Sentiment Trading

Xbrane Biopharma AB has completed the sale of its R&D organization and a biosimilar candidate to Alvotech for approximately $28.9 million, marking a strategic shift for the company.

Xbrane Biopharma AB is navigating market fluctuations by focusing on complex generics, positioning itself for future growth and addressing global demand for affordable biopharmaceuticals.